Tag - neoplasie polmone
Tarlatamab for Patients with Previously Treated Small...
A Phase 3, Randomized study of atezolizumab plus...
Association Between Duration of Immunotherapy and...
Risk of Further Progression or Death Among Durable...
Perioperative Nivolumab and Chemotherapy in Stage III...
Lobar or Sublobar Resection for Peripheral Stage IA...
Adjuvant Osimertinib for Resected EGFR-Mutated Stage...
Five-Year Survival Outcomes With Nivolumab Plus...
Pembrolizumab versus placebo as adjuvant therapy for...
Adebrelimab or placebo plus carboplatin and etoposide...
Neoadjuvant Nivolumab plus Chemotherapy in Resectable...
Genomic Profiling of Lung Adenocarcinoma in Never...
Benefits and Harms of Lung Cancer Screening by Chest...
Adjuvant atezolizumab after adjuvant chemotherapy in...
Nivolumab Plus Ipilimumab vs Nivolumab for Previously...
Intracranial and extracranial efficacy of lorlatinib...
Sotorasib for Lung Cancers with KRAS p.G12C Mutation
Updated Integrated Analysis of the Efficacy and Safety...
First-line nivolumab plus ipilimumab combined with two...
Continuous Versus 1-Year Fixed-Duration Nivolumab in...
Gefitinib Versus Vinorelbine Plus Cisplatin as...
Durvalumab, with or without tremelimumab, plus...
Capmatinib In MET Exon 14–Mutated Or MET-Amplified...
Efficacy of Selpercatinib in RET Fusion–Positive...
Tepotinib in Non–Small-Cell Lung Cancer with MET Exon...
Patient-reported outcomes following pembrolizumab or...
Lorlatinib in Advanced ROS1-positive Non-Small-Cell...
Evaluation of POLE and POLD1 Mutations as Biomarkers...
Association of Early Palliative Care Use With Survival...
Cost Effectiveness of Multigene Panel Sequencing for...
Will That Pulmonary Nodule Become Cancerous? A Risk...
Lung Cancer Incidence and Mortality with Extended...
Neoplasie del polmone 2017
Neoplasie del polmone 2016
Neoplasie del polmone 2015
Neoplasie del polmone 2014
Neoplasie del polmone 2013
Neoplasie del polmone 2012
